购物车
- 全部删除
- 您的购物车当前为空
FRAX597 是一种有效的 ATP 竞争性 I 组 PAK 抑制剂,作用于PAK1、2和3,IC50分别为 8、13 和 19 nM。
为众多的药物研发团队赋能,
让新药发现更简单!
FRAX597 是一种有效的 ATP 竞争性 I 组 PAK 抑制剂,作用于PAK1、2和3,IC50分别为 8、13 和 19 nM。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
1 mg | ¥ 289 | 现货 | |
2 mg | ¥ 413 | 现货 | |
5 mg | ¥ 828 | 现货 | |
10 mg | ¥ 1,390 | 现货 | |
25 mg | ¥ 2,390 | 现货 | |
50 mg | ¥ 3,570 | 现货 | |
100 mg | ¥ 5,160 | 现货 | |
500 mg | ¥ 10,800 | 现货 |
产品描述 | FRAX597 is an effective, ATP-competitive inhibitor of group I PAKs, and for PAK1(IC50=8 nM), PAK2(IC50=13 nM), and PAK3 (IC50=19 nM). |
靶点活性 | PAK3:19 nM, PAK1:8 nM, PAK2:13 nM |
体外活性 | 负荷Nf2-/-SC4 Schwann细胞的NOD/SCID小鼠中,每天口服 FRAX597(100 mg/kg),对肿瘤生长有明显的抑制作用.患有原位脑膜瘤的SCID小鼠中,每天口服 FRAX597(90 mg/kg),明显抑制肿瘤生长.在KrasG12D小鼠中,每天口服 FRAX597(90 mg/kg),处理引起肿瘤消退以及Erk与Akt活性损失. |
体内活性 | FRAX597抗野生型PAK1(IC50=48 nM),而抗V342F PAK1突变型(IC50>3 μM)和V342Y PAK1突变型(IC50>2 μM)。FRAX597(100 nM )对YES1 (87%),RET (82%),CSF1R (91%),TEK (87%),PAK1 (82%),和PAK2 (93%)表现出明显的抑制作用。 |
激酶实验 | Determination of Enzyme IC50 Values: IC50 values are determined using a 10 concentration point, non-radioactive, functional assay that employs a fluorescence-based, coupled-enzyme format, according to the manufacturer's protocol (Z'-LYTE@biochemical assay). Kinase selectivity is determined using both the Z'-LYTE@ and Adapta@ kinase assay format. |
细胞实验 | 30,000 cells/well are plated in 12-well dishes in triplicate. Cell growth media with or without FRAX597 is replaced daily. At indicated time points, cells from individual wells are trypsinized and counted using a Coulter counter.(Only for Reference) |
分子量 | 558.1 |
分子式 | C29H28ClN7OS |
CAS No. | 1286739-19-2 |
Smiles | CCn1c2nc(Nc3ccc(cc3)N3CCN(C)CC3)ncc2cc(-c2ccc(cc2Cl)-c2cncs2)c1=O |
密度 | no data available |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
溶解度信息 | DMSO: 1 mg/ml, Sonication is recommended. |
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.
评论内容